Patient and sample characteristics (Figure 1B; supplemental Figure 1A)
| ID . | Sex . | Age, y . | IgVH . | ZAP-70 . | Genetic aberration . | Binet stage . | Previous therapy . |
|---|---|---|---|---|---|---|---|
| UM1 | Male | 75 | UM | Negative | Del11q, Del13q, Del14q | A | None |
| UM2 | Male | 61 | UM | Negative | Del11q, Del13q | NA | F, FCA, hu anti-CD20 |
| UM3 | Male | 73 | UM | Negative | Del13q, Gain12q | B | Clb |
| UM4 | Male | 66 | UM | Positive | Del11q, Gain12q, t(14q32) | A | None |
| UM5 | Female | 62 | UM | ND | Del11q | B | Clb, F, CHOP, A |
| UM6 | Male | 62 | UM | ND | Del11q, Del13q | A | F |
| UM7 | Female | 79 | UM | ND | Gain12q | A | FC |
| 17p− 1 | Female | 52 | UM | Negative | Del17p | C | None |
| 17p− 2 | Female | 66 | UM | Positive | Del17p, Del14q32 | C | B, FCR |
| 17p− 3 | Female | 43 | UM | ND | Del17p | A | RB, RC |
| 17p− 4 | Male | 71 | UM | Negative | Del17p, Del11q, Del13q | B | None |
| 17p− 5 | Male | 77 | UM | Negative | Del17p, Del13q | C | None |
| M1 | Male | 53 | M | Negative | Del13q | B | None |
| M2 | Female | 80 | M | Negative | Del13q | C | None |
| M3 | Female | 75 | M | Negative | Del13q | A | None |
| M4 | Female | 65 | M | Negative | None | A | None |
| M5 | Male | 72 | M | Negative | Del13q | A | None |
| M6 | Male | 81 | M | ND | Del13q | A | F |
| M7 | Male | 60 | M | Negative | Del13q | A | F |
| ID . | Sex . | Age, y . | IgVH . | ZAP-70 . | Genetic aberration . | Binet stage . | Previous therapy . |
|---|---|---|---|---|---|---|---|
| UM1 | Male | 75 | UM | Negative | Del11q, Del13q, Del14q | A | None |
| UM2 | Male | 61 | UM | Negative | Del11q, Del13q | NA | F, FCA, hu anti-CD20 |
| UM3 | Male | 73 | UM | Negative | Del13q, Gain12q | B | Clb |
| UM4 | Male | 66 | UM | Positive | Del11q, Gain12q, t(14q32) | A | None |
| UM5 | Female | 62 | UM | ND | Del11q | B | Clb, F, CHOP, A |
| UM6 | Male | 62 | UM | ND | Del11q, Del13q | A | F |
| UM7 | Female | 79 | UM | ND | Gain12q | A | FC |
| 17p− 1 | Female | 52 | UM | Negative | Del17p | C | None |
| 17p− 2 | Female | 66 | UM | Positive | Del17p, Del14q32 | C | B, FCR |
| 17p− 3 | Female | 43 | UM | ND | Del17p | A | RB, RC |
| 17p− 4 | Male | 71 | UM | Negative | Del17p, Del11q, Del13q | B | None |
| 17p− 5 | Male | 77 | UM | Negative | Del17p, Del13q | C | None |
| M1 | Male | 53 | M | Negative | Del13q | B | None |
| M2 | Female | 80 | M | Negative | Del13q | C | None |
| M3 | Female | 75 | M | Negative | Del13q | A | None |
| M4 | Female | 65 | M | Negative | None | A | None |
| M5 | Male | 72 | M | Negative | Del13q | A | None |
| M6 | Male | 81 | M | ND | Del13q | A | F |
| M7 | Male | 60 | M | Negative | Del13q | A | F |
UM indicates unmutated; NA, not applicable; M, mutated, ND, not done; F, fludarabine; C, cyclophosphamide; A, alemtuzumab; FCA, fludarabine, cyclophosphamide, alemtuzumab; hu, human; Clb, chlorambucil; CHOP, cyclophosphamide, doxorubicin, vincristin, prednisone; B, bendamustin; and R, rituximab.